LONDON (Thomson Financial) - ReGen Therapeutics Plc. said it is sees market
value of about $2.2 million in the first-half from the Colostrinin/CogniSure
drug ordered by Metagenics Inc. based on the number of kilos ordered and
assuming all are sold.
ReGen is a biotechnology company.
TFN.newsdesk@thomson.com
ash/jfr
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|